In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK buys ID Biomedical for $1.4bn

Executive Summary

GlaxoSmithKline PLC has agreed to acquire Canadian vaccine developer ID Biomedical for $1.4bn ($Cdn1.6bn) in cash. GSK is paying $29.45 ($Cdn35) per share, a 17% premium to the market average. Included in the price is GSK's assumption of the company's $77mm debt.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies